Boston Scientific Exceeds Wall Street’s Expectations In Q3

Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.

Sep 16, 2019 Fremont / CA / USA - Boston Scientific office buildings in Silicon Valley; Boston Scientific Corporation is a manufacturer of medical devices used in interventional medical specialties
• Source: shutterstock.com

Boston Scientific’s third-quarter 2020 revenue total is higher than Wall Street analysts expected it to be, but it is still lower than it was a year ago due to the slowdown in procedures caused by the pandemic.

The company generated nearly $2.7bn in sales during the third quarter of 2020, representing a 2.5% decline on an operational...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from R&D

More from Business